Supplementary Figure 5: Validation of changes in DNA methylation between multiple sclerosis and controls in an independent cohort of samples.
From: Epigenome-wide differences in pathology-free regions of multiple sclerosis–affected brains
(a) Plot of DNA methylation levels for individual CpGs within a window of the CTSZ DMR as measured by Illumina array of the discovery cohort. Methylation levels for individual MS cases and controls are plotted in red and black, respectively, with red and black lines connecting the mean methylation level for each consecutive CpG assayed. Arrowheads indicate CpGs that were assayed in a second cohort (b). (b) Methylation levels for individual CpGs assessed using MassARRAY EpiTYPER of a second cohort. Plots are as shown in (a) for the CpGs marked by arrowheads. Arrowheads indicate CpGs with corresponding Illumina probes in (a). (c–d) Same as described in (a,b) for a window of the SLC47A2 DMR. MS, multiple sclerosis.
